SGMT
Sagimet Biosciences Inc.
Next earnings Aug 17, 2026 (before open) · consensus $-0.25 EPS
Last earnings -0.5% on 2026-05-12
$6.86▼ -21.33%
over 1Y
L $4.55EODHDH $10.24
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W+2.7%
1M-5.0%
3M+34.2%
YTD+14.5%
1Y-21.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 18 analysts
Buy
Conservative balance sheet (liabilities/equity 0.05x); but unprofitable (net margin -2551.9%).
Sagimet Biosciences Inc. shows $2.00M in FY2023 revenue, a -2551.9% net margin, and -45.8% ROE.
Sources: SEC EDGAR (CIK 0001400118, latest 10-Q filed 2026-05-12) · as of 6/26/2026, 7:26:13 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.